Why is GSK stock sliding today?

GSK plc's stock fell 4.6% after its Q3 2026 earnings report, despite beating EPS and sales estimates. Vaccine revenues declined, and operating profit dropped 16%. The company expects lower core EPS growth for the year. Barclays maintained a Sell rating, and the FTSE 100's decline added to the pressure, pushing GSK shares to an intraday low of 1823p.

Original reporting
Published Oct 28, 2026, 8:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GSK
Bearish
high confidence
Mentioned
$GSK
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GSKBearishHigh
01

Why it matters

The earnings surprise and guidance downgrade triggered a 4.6% intraday decline, highlighting investor sensitivity to vaccine revenue trends.

02

Market read

The earnings release is the primary catalyst for GSK's share slide and may influence broader pharma sentiment.

03

What to watch

Potential upside from upcoming pipeline products and long‑term vaccine contracts not reflected in the short‑term numbers.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

GSK's Q3 results were released before the London open, showing mixed performance with core EPS beat but weaker vaccine sales and higher financing costs.

Company-level read

Ticker impact

$GSKBearishHigh confidence
Context

GSK reported Q3 2026 earnings with core EPS beat but vaccine revenue decline and lower‑half guidance, causing a 4.6% share drop.

Expected impact

likely further downside as investors price in weaker guidance and higher debt costs

Evidence & confidence

The earnings release includes new guidance and a restructuring charge that were not previously public, and the stock already fell 4.6% intraday.

Market effects

Healthcare sector may face pressure as vaccine revenue concerns spread to peers.

UK market sentiment weakened, dragging FTSE 100 lower.

Limited to GSK and related vaccine manufacturers; no broad macro impact.

Counterpoint

If the market overreacts to short‑term vaccine dip, the stock could rebound on solid core earnings.

Key entities

  • GSK plc

    British pharmaceutical giant reporting Q3 2026 earnings.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$GSKMed

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.